University of California Irvine is the first California site participating in Celularity’s CYNK-001-COVID-19 clinical trial NCT04365101 using Celularity’s investigational immunotherapy to treat adults who tested COVID-19 positive in underserved and...
Celularity, a New Jersey company developing experimental cancer treatments derived from human placentas, has received the FDA’s blessing to kick off human testing of its lead immunotherapy for cases of...
Celularity announces the activation of first California Clinical Trial Site following CIRM Grant Award to Advance Treatments for COVID-19
Celularity to Test Natural Killer Cell Therapy for Cancer Against COVID